Innovation Pharmaceuticals Inc (IPIX)

[frrol]

Retail investors always need to keep in mind that the "top line" results we see are the tip of the iceberg. There is supporting PK/PD data, all the trial protocols, patient specs, etc. They have to be regressed, analyzed, double-checked. I've gotten glimpses into the process and it's surprisingly complex (though it shouldn't be). As evidence, note that data and conclusions will continue to dribble out for our B-OM trial; witness the recent release of the B-OM sub-grouping. This information you would think would pop out from the first regressions. In fact it may have, but needed to be verified and refined.